Artenimol-piperaquine in children with uncomplicated imported falciparum malaria: experience from a prospective cohort.
Artenimol–piperaquine
Children
Imported malaria
QTc interval
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
16 Dec 2019
16 Dec 2019
Historique:
received:
13
08
2019
accepted:
30
11
2019
entrez:
18
12
2019
pubmed:
18
12
2019
medline:
8
5
2020
Statut:
epublish
Résumé
Although malaria remains one of the major public health threats in inter-tropical areas, there is limited understanding of imported malaria in children by paediatricians and emergency practitioners in non-endemic countries, often resulting in misdiagnosis and inadequate treatment. Moreover, classical treatments (atovaquone-proguanil, quinine, mefloquine) are limited either by lengthy treatment courses or by side effects. Since 2010, the World Health Organization (WHO) has recommended the use of oral artemisinin-based combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria worldwide. The benefits of artenimol-piperaquine in children have been validated in endemic countries but experience remains limited in cases of imported malaria. This prospective observational study in routine paediatric care took place at the Emergency Department, Robert-Debré Hospital (Paris, France) from September 2012 to December 2014. Tolerance and efficacy of artenimol-piperaquine in children presenting with the following inclusion criteria were assessed: P. falciparum positive on thin or thick blood smear; and the absence of WHO-defined features of severity. Among 83 children included in this study, treatment with artenimol-piperaquine was successful in 82 children (98.8%). None of the adverse events were severe and all were considered mild with no significant clinical impact. This also applied to cardiological adverse events despite a significant increase of the mean post-treatment QTc interval. Artenimol-piperaquine displays a satisfying efficacy and tolerance profile as a first-line treatment for children with imported uncomplicated falciparum malaria and only necessitates three once-daily oral intakes of the medication. Comparative studies versus artemether-lumefantrine or atovaquone-proguanil would be useful to confirm the results of this study.
Sections du résumé
BACKGROUND
BACKGROUND
Although malaria remains one of the major public health threats in inter-tropical areas, there is limited understanding of imported malaria in children by paediatricians and emergency practitioners in non-endemic countries, often resulting in misdiagnosis and inadequate treatment. Moreover, classical treatments (atovaquone-proguanil, quinine, mefloquine) are limited either by lengthy treatment courses or by side effects. Since 2010, the World Health Organization (WHO) has recommended the use of oral artemisinin-based combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria worldwide. The benefits of artenimol-piperaquine in children have been validated in endemic countries but experience remains limited in cases of imported malaria.
METHODS
METHODS
This prospective observational study in routine paediatric care took place at the Emergency Department, Robert-Debré Hospital (Paris, France) from September 2012 to December 2014. Tolerance and efficacy of artenimol-piperaquine in children presenting with the following inclusion criteria were assessed: P. falciparum positive on thin or thick blood smear; and the absence of WHO-defined features of severity.
RESULTS
RESULTS
Among 83 children included in this study, treatment with artenimol-piperaquine was successful in 82 children (98.8%). None of the adverse events were severe and all were considered mild with no significant clinical impact. This also applied to cardiological adverse events despite a significant increase of the mean post-treatment QTc interval.
CONCLUSION
CONCLUSIONS
Artenimol-piperaquine displays a satisfying efficacy and tolerance profile as a first-line treatment for children with imported uncomplicated falciparum malaria and only necessitates three once-daily oral intakes of the medication. Comparative studies versus artemether-lumefantrine or atovaquone-proguanil would be useful to confirm the results of this study.
Identifiants
pubmed: 31843017
doi: 10.1186/s12936-019-3047-9
pii: 10.1186/s12936-019-3047-9
pmc: PMC6915931
doi:
Substances chimiques
Artemisinins
0
Quinolines
0
piperaquine
A0HV2Q956Y
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
419Références
Blood. 2014 Jul 10;124(2):167-75
pubmed: 24859359
PLoS One. 2009 Nov 17;4(11):e7871
pubmed: 19936217
J Infect. 2007 Feb;54(2):111-21
pubmed: 17215045
Arch Dis Child Educ Pract Ed. 2013 Feb;98(1):7-15
pubmed: 23171589
Drugs. 2012 May 7;72(7):937-61
pubmed: 22515619
Infection. 2018 Dec;46(6):867-870
pubmed: 29980936
Pediatr Infect Dis J. 2012 Jan;31(1):102; author reply 102-3
pubmed: 22217970
Lancet Infect Dis. 2017 Feb;17(2):184-193
pubmed: 27865890
PLoS One. 2010 Jul 30;5(7):e11880
pubmed: 20689583
Malar J. 2016 Jul 02;15(1):339
pubmed: 27368160
Malar J. 2015 Jan 28;14:27
pubmed: 25626448
Malar J. 2012 Sep 17;11:328
pubmed: 22985344
Science. 1985 May 31;228(4703):1049-55
pubmed: 3887571
Lancet. 2018 Apr 21;391(10130):1608-1621
pubmed: 29631781
Br J Clin Pharmacol. 2004 Jan;57(1):93-9
pubmed: 14678346
Can Commun Dis Rep. 2009 Jul;35 Suppl 1:1-82
pubmed: 19750611
Emerg Infect Dis. 2016 Aug;22(8):1381-6
pubmed: 27434054
Antimicrob Agents Chemother. 2012 Jun;56(6):3261-70
pubmed: 22391528